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The characteristics of breast cancer patients  
with metachronous primary malignancies
Beata Sas-Korczyńska1, Wojciech Kamzol1, Marta Kołodziej-Rzepa2, Wojciech M. Wysocki2
Introduction. The risk of developing subsequent primary cancers varies from 1% to 18% and it depends on the type 
of first cancer and treatment methods applied. Considering the time of occurrence, multiple primary cancers gene-
rally fall into two categories: synchronous and metachronous. In breast cancer patients, 10.5% developed multiple 
primary cancers, from which 23.8% had synchronous, 79% had metachronous and the remaining 2.8% had both 
synchronous and metachronous malignancies. In patients with breast cancer, elevated risk is observed especially in 
the development of contralateral breast cancer, endometrial, esophageal cancer, ovarian cancer and thyroid cancer.
Aim. This paper presented the characteristics of breast cancer patients with metachronous primary malignancies in 
relation to the type of metachronous primaries (breast versus non-breast) and to analyse the impact of the type of 
metachronous cancers on survival rate.
Material and methods. Among patients treated for breast cancer between 1963 and 2010, 354 patients (2.1%) deve-
loped metachronous primary malignancies and these made up 13.8% of all patients with multiple primary cancers. 
The mean age at diagnosis of the first breast cancer was 53 ± 11.5 years; positive family cancer history was noted in 
127 patients (35.9%). Metachronous malignancies are defined as primaries following the diagnosis of breast cancer 
in a time interval greater than or equal to than 6 months. In our group, the mean time interval between the diagnosis 
of breast cancer and the appearance of metachronous malignancies was 100.9 ± 74.9 months (range: 6–543 months, 
median: 83 months). 
For comparison of the two groups (patients with second breast vs non-breast cancer) we used the Pearson’s Chi-square 
test for independence (for categorized variables) and variance analysis with Student’s t-test (for continuous variables). 
The survival rate was evaluated with the Kaplan-Meier method, and the log rank test was applied to assess the influ-
ence of some factors on the evaluated results. The significance level at α = 0.05 was adopted for all statistical analyses.
Results. The probability of occurrence of new cancer averaged from 38.1% to 67.8% for 5 and 10 years after diagnosis 
of first breast cancer, respectively. In our group, 380 cases of metachronous carcinomas were noted in 354 analysed 
patients. The most frequent metachronous malignancy was breast cancer (194 cases — 54.8%), which occurred as 
second (192 cases) or third (2 cases) cancer. Patients with contralateral breast cancer in comparison to other types of 
metachronous malignancies were significantly (p < 0.05): younger (under 50 years: 56.2% vs 34.4%), premenopausal 
(69.6% vs 48.8%), had a lobular type of first breast cancer (6.7% vs 1.3%), and rarely received tamoxifen (25.3% vs 
48.2%). The type of metachronous cancers significantly influenced survival rate: 10-year overall survival rates were 
80.1% vs 67.8%, (p = 0.0271).
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Conclusions. The risk of occurrence of second malignancies in breast cancer survivors makes early detection of 
metachronous malignancies obligatory because it is an important factor which influences the quality of life in breast 
cancer survivors.
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Introduction
The advances in cancer therapy, early detection and 
supportive care have contributed to the improvement of 
survival rates. About 70% of all cancer patients survive at 
least five years after diagnosis. The number of cancer survi-
vors is growing rapidly, by about 2% each year. Therefore, 
the identification of the subsequent effects of cancer and 
its treatment has become a critical problem due to their 
long-term clinical and physiological importance. One of 
these late events is the diagnosis of a new cancer in cancer 
survivors — a second, third or higher-order primary in some 
cases [1–6].
Published data indicate that the risk of developing sub-
sequent primary cancers varies from 1% to 18%, and this 
depends on the type of first cancer and used treatment 
methods [3, 6–11].
Causal mechanisms of multiple primary cancer deve-
lopment include genetic predispositions, environmental 
exposures, lifestyle factors as well as late sequelae of cancer 
treatment (cytotoxic, radiation or hormonal therapies), its 
results and a combination of these mechanisms [1, 3–5, 8, 
9, 12, 13]. The risk of second primaries also depends on pa-
tient age and the amount of time elapsed since anticancer 
therapy [3, 4, 14–16]. According to data published by Lee 
et al., the 30-year overall cumulative incidence of second 
malignancies amounts to 5.2% for children (aged ≤ 14 years), 
13.9% for adolescents and young adults (aged 15–39 years) 
and 16.8% for adults (aged ≥ 40 years) [4].
The definition of multiple primary cancers is based on 
the classic criteria of Warren and Gates which include 1) 
the site of origin — tumours arise in different organs than 
independent primaries, 2) morphology and histology of 
tumours — each tumour has to be histologically distincti-
ve and the possibility of metastasis or recurrence must be 
excluded, and 3) the amount of time elapsed since the initial 
diagnosis [7, 9, 10]. Considering the time of occurrence, 
multiple primary cancers generally fall into two categories: 
1) synchronous, if the cancers occur at the same time or within 
2–6 months, and 2) metachronous, if the primaries follow 
in sequence in a interval time interval of more than 2–6 
months [1, 5, 9, 10]. It should be noted that the time interval 
distinguishing synchronous and metachronous malignan-
cies has not been precisely defined in literature. However, 
a time interval of 6 months between the occurrence of two 
primaries has been accepted by some authors [1, 9]. Breast 
cancer is the most common cancer in women; in 2012 it 
was diagnosed in 1.7 million women in the world, and in 
17 thousand women in Poland [17, 18]. In these patients, 
continuously improving survival rates have been observed 
and, therefore, after effective therapy, the majority of them 
become long-term survivors with elevated risk of occurrence 
of second malignancies [16, 19–22]. 
The risk of developing multiple primary malignancies 
in breast cancer survivors is increased in the case of posi-
tive family history, the presence of a mutation in tumour 
suppressor genes (BRCA1, BRCA2, PTEN, TP53) as well as in 
survivors with negative family history. Other factors which 
potentially can influence the risk of second malignancy 
include age, body weight, alcohol intake, hormonal repla-
cement therapy and breast cancer therapy [15, 20, 22–24].
According to Lee et al., 10.5% of breast cancer patients 
had multiple primary cancers, of which 23.8% had synchro-
nous, 79% had metachronous and the remaining 2.8% had 
both synchronous and metachronous malignancies [9]. In 
patients with an initial diagnosis of breast cancer, elevated 
risk is observed especially in the development of contrala-
teral breast cancer, endometrial cancer, esophageal cancer, 
ovarian cancer and thyroid cancer [7].
The purpose of this study was 1) to present the cha-
racteristics of breast cancer patients with metachronous 
primary malignancies, 2) to compare the characteristics 
in relation to the type of metachronous primaries (breast 
versus non-breast) and 3) to analyse the impact of the type 
of metachronous cancers on survival rate.
Material and methods
Patients
Between 1963 and 2010, 17,066 patients with breast can-
cer were treated at Maria Skłodowska-Curie Memorial Cancer 
Centre and Institute of Oncology in Krakow. Of these, 354 pa-
tients (2.1%) developed metachronous primary malignancies 
and they made up 13.8% of all patients with multiple primary 
cancers. The mean age at diagnosis of the first breast cancer 
was 53 ± 11.5 years (range: 26–83, median: 51 years). Positive 
caner family history was noted in 127 patients (35.9%). Meta-
chronous contralateral breast cancer appeared in 50 patients 
with breast cancer positive family history, comprising 14.1% 
of all patients and 39.4% of patients with positive family 
16
history. Benign breast diseases and/or hormonal disturbances 
were found in 33 individuals (9.3%). 
The clinicopathological characteristics of 354 patients 
with first breast cancer and metachronous primary mali-
gnancies are presented in Table I.
The majority of these patients (75.2%) had at an early 
stage (pT1–2) of the disease at the time of diagnosis of first 
breast cancer; however, in 52.5% of patients the axillary 
lymph node metastases were confirmed in pathological 
examination. 
Because patients with first breast cancer and metachrono-
us cancers were managed over a period of 47 years, the dia-
gnostic methods and the spectra of treatment changed along 
with the indications. Nevertheless, surgery was the primary 
treatment modality in all presented patients; radical mastec-
tomy was performed in 337 cases (95.2%), whereas 17 patients 
(4.8%) underwent breast-conserving surgery. The following 
adjuvant therapy was applied: postoperative radiotherapy 
(113 patients — 31.9%), chemotherapy (137 patients — 38.7%) 
and hormonotherapy (140 patients — 39.5%), which in 127 
patients (35.8%) was combined with tamoxifen. In some cases, 
multimodal treatment was performed in an adjuvant setting.
Metachronous primary malignancies  
after breast cancer
In this article, metachronous malignancies are defined 
as primaries following the diagnosis of breast cancer in a ti- 
me interval greater than or equal to 6 months. 
The mean time interval between the diagnosis of breast 
cancer and the appearance of metachronous malignancies 
was 100.9 ± 74.9 months (range: 6–543 months, median: 83 
months). In most patients (220 of 354 — 62.1%) metachro-
nous malignancies developed later than 60 months after 
the initial diagnosis of breast cancer.
In 354 patients treated primarily for breast cancer, 380 
cases of metachronous carcinomas were noted, including 
Table I. Characteristics of 354 patients with breast cancer who developed metachronous primary cancers
Parameters (at diagnosis of first breast cancer) No. of patients %
Age (years)
≤ 50 164 46.3
> 50 190 53.7
Menopausal status
Premenopausal 213 60.2
Postmenopausal 141 39.8
Family history (positive) 127 35.9
Breast cancer 38 10.7
Breast cancer and other cancers 12 3.4
Other cancers 77 21.8
Breast disease and other symptoms 33 9.3
Benign breast diseases (fibrocystic changes, hyperplasia) 14 4.0
Hormonal disturbances (hormone replacement therapy, pregnancy-related breast cancer, adnexitis) 17 4.8
BRCA1 or BRCA2 mutation 2 0.6
Histological type
Ductal 298 84.1
Lobular 15 4.2
Othera 41 11.6
Stage of breast cancer
pT 1 77 21.8
pT 2 189 53.4
pT 3 43 12.1
pT 4 35 10.0
pT xb 10 2.8
pN 0 167 47.2
pN+ 186 52.5
pN xb 1 0.3
aOther types of first breast cancer: medullary (12 pts.), mucinous (9 pts.), metaplastic (9 pts.), apocrine (3 pts.), tubular (3 pts.), inflammatory (2 pts.), Paget’s disease of the 
nipple (2 pts.), papillary (pt.); bunknown
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354 cases of second cancer and, additionally, 24 cases of 
third cancer and 2 cases of fourth cancer. 
The types of all 380 metachronous malignancies are 
presented in Table II. 
The most frequent metachronous malignancy was 
breast cancer (194 cases — 54.8%), which occurred as se-
cond (192 cases) or third (2 cases) cancer. 
Statistical methods
In the studied population, two groups were distingu-
ished: patients with metachronous contralateral breast can-
cer (all patients who developed breast cancer as metachro-
nous primary morbidity) and patients with metachronous 
non-breast cancer. 
The Pearson’s Chi-square test for independence (for 
categorized variables) and variance analysis with Student’s 
t-test (for continuous variables) were used for comparison 
of the two groups to assess the relation to the frequency of 
the factors analysed.The survival rate (overall and without 
metachronous maligancies) was evaluated with the Kaplan-
-Meier method, and the log rank test was applied to assess 
the influence of some factors on the evaluated results.
All calculations were performed by STATISTICA v.12 soft- 
ware (StatSoft, Inc. Tulsa, OK, USA) and the significance level 
at a = 0.05 was adopted for all statistical analyses. 
Results
The probability of occurrence of new cancer averaged 
from 38.1% to 67.8% for 5 and 10 years after diagnosis of 
first breast cancer, respectively. 
Figure 1 shows the probability of appearance of me-
tachronous primaries in relation to their type (breast or 
non-breast). Lower tendency for the probability of the oc-
currence of the second breast cancer (or metachronous con-
tralateral breast cancer) in comparison to the appearance of 
other types of metachronous primaries was noted (36.5% 
vs 40.1% for 5 years and 64.1% vs 72.2% for 10 years; p = 
0.05504, log rank test).
Table III presents the results of the comparison of pa-
tients characteristics in relation to the type of metachronous 
malignancy: breast versus non-breast cancers.
Performed analysis showed statistically significant diffe-
rences between these groups in relation to age, menopausal 
status, histological type of first breast cancer and implemen-
Table II. The types of 380 metachronous primary cancers, which developed in 354 patients after treatment for first breast cancer
Diagnosis of metachronous cancers No. of all cases % Metachronous primaries developed as morbidity:
2nd 3rd 4th
Total 380 100.0 354 24 2
Breast cancer (in contralateral breast) 194 51.1 192 2 -
Female genital organ cancers: 83 21.8 73 10 -
Endometrial cancer 30 7.9 29 1 -
Ovarian cancer 29 7.6 23 6 -
Cervical uteri cancer 21 5.5 19 2 -
Vaginal cancer 2 0.5 1 1 -
Vulvar cancer 1 0.3 1 - -
Digestive organ cancers: 24 6.3 22 2 -
Oesophageal and stomach cancer 8 2.1 7 1 -
Colon cancer 6 1.6 5 1 -
Rectal cancer 6 1.6 6 - -
Biliary tract and pancreatic cancer 4 1.1 4 - -
Skin neoplasms: 21 5.5 18 2 1
Melanoma 10 2.6 9 1 -
Carcinoma 11 2.9 9 1 1
Lung cancer 16 4.2 10 5 1
Urinary tract cancers: 13 3.4 11 2 -
Kidney cancer 9 2.4 7 2 -
Bladder cancer 4 1.1 4 - -
Thyroid cancer 9 2.4 9 - -
Lymphatic tissue neoplasms 9 2.4 8 1 -
Head and neck, eye and brain cancers 7 1.8 7 - -
Soft tissue and bone sarcomas 4 1.1 4 - -
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tation of tamoxifen. Patients who developed metachronous 
contralateral breast cancer, in comparison to patients with 
metachronous non-breast cancers, were significantly youn-
ger (mean age 50.9 vs 55.5 years; p = 0.00018). The most of 
them were younger than 50 years of age (56.2% vs 34.4%; 
p = 0.00005), in premenopause (69.6% vs 48.8%; p = 0.00007), 
had lobular type of first breast cancer (6.7% vs 1.3%; 
p = 0.04031) and did not use tamoxifen in adjuvant therapy 
for first breast cancer (74.7% vs 51.3%; p < 0.00001). More-
over, patients with lobular type of first breast cancer more 
frequently developed metachronous contralateral breast 
cancer than other type of metachronous malignancies 
(13 patients — 86.7% vs 2 patients — 13.3%; p = 0.04031). 
Additionally, it was noted that the type of metachronous 
cancer (breast or non-breast) had significant influence on 
survival (Fig. 2).
The estimated 5-year and 10-year overall survival rates 
were: 92.9% and 80.1%, respectively (for metachronous 
contralateral breast cancer) and 91.3% and 67.8%, respec-
tively (for metachronous non-breast cancer); p = 0.02710, 
log rank test.
The follow-up period since the diagnosis of first breast 
cancer ranged from 7 to 558 months with mean value: 180 ± 
108.7 months and median: 168.5 months. During this period 
195 patients (55.1%) died and the causes of death were as 
following: second cancer (106 cases), third cancer (6 cases), 
coexistent non-cancer internal diseases (50 patients), and 
unknown (33 patients). 
The estimated 5- and 10-year overall survival rates were: 
91.8% and 74.5%, respectively (Fig. 3).
The clinical observation showed that 71 patients (20.1%) 
developed distant metastases in mean period of 28 ± 27.3 
months (range: 1–136 months, median: 18 months). The 
localisations of this failure were as following: bones (28 
cases), liver (12 cases), brain (11 cases), lungs (11 cases), 
distant lymph nodes (11 cases), skin (5 cases), pleura (1 ca- 
se), peritoneum (1 case).
Furthermore, local/regional recurrence of breast cancer 
was noted in 59 patients (16.7%). In 31 patients (8.8%) this 
failure concerned the first breast cancer and it occurred in 
mean period of 50.2 ± 50.2 months (range: 2–234 months, 
median: 36 months). In remaining 28 patients (7.9%) recur-
rence of second breast cancer was observed and it develop- 
ed between 3 and 97 months (mean: 26.8 ± 22.1, median: 
19.0 months) after diagnosis of second breast cancer.
Discussion
Published data indicate that women with breast cancer 
have an increased risk of developing second primaries. The 
results of meta-analysis performed by Molina-Montes et 
al. indicate that the risk of second cancer in breast cancer 
patients is increased by 17% in comparison with the general 
population, and this risk is relative to age at diagnosis of 
the first breast cancer and the time interval between the 
occurrence of the first and second malignancies. Women 
younger than 50 years have a 51% increase in risk in com-
parison to an 11% increase in women aged over 50 years. 
Furthermore, the risk of second malignancy after breast 
cancer is increased by 19% within the first 10 years and by 
26% after 10 years [15]. 
Published data indicate that age as well as menopausal 
status at diagnosis of breast cancer are important predic-
tors of second primaries [16, 24–34]. Langballe et al., who 
investigated the risk of second malignancies in relation to 
Figure 1. The probability of metachronous primary cancers in relation to the type of metachronous primaries: breast vs non-breast cancer
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menopausal status in women with breast cancer, noted 
that premenopausal women had an 18% increase in risk of 
appearance of second malignancy and this increased risk 
was confined to endometrial and ovarian cancers. Moreover, 
in postmenopausal women the risk of cervical cancer was 
significantly reduced. The authors speculated that these 
observations resulted from intensified screening in compa-
rison to the general population, and are related to different 
lifestyle factors and socioeconomic status [25].
In the studied group, 60.2% of women (213 of 354) were 
premenopausal at diagnosis of breast cancer, while 46.3% 
(164 of 354) were younger than 50 years of age. The compa-
rison of characteristics of patients with metachronous breast 
vs non-breast malignancies showed significant differences 
Table III. The comparison of patient characteristics in relation to the type of metachronous primary cancers: breast cancer vs non-breast cancer 
Parameters (at diagnosis of first breast cancer) Metachronous primaries
breast
n = 194 (100%)
non-breast
n = 160 (100%)
p
Age (years): 
Mean value 50.9 55.5 0.00018a
≤ 50 109 (56.2%) 55 (34.4%) 0.00005
> 50 85 (43.8%) 105 (65.6%)
Menopausal status:
Premenopausal 135 (69.6%) 78 (48.8%) 0.00007
Postmenopausal 59 (30.4%) 82 (51.3%)
Family history of cancers:
Negative 130 (67%) 97 (60.6%)
Breast cancers 30 (15.5%) 20 (12.5%) 0.09894
Other cancers 34 (17.5%) 43 (26.9%)
Breast disease and other symptoms:
None 145 (90.6%) 176 (90.7%)
Benign breast disease 4 (2.5%) 10 (5.2%)
Hormonal disturbances 10 (6.3%) 7 (3.6%) 0.41446
BRCA1 or BRCA2 mutation 1 (0.6%) 1 (0.5%)
Histological type:
Ductal 159 (82%) 139 (86.9%)
Lobular 13 (6.7%) 2 (1.3%) 0.04031
Other 22 (11.3%) 19 (11.9%)
Stage of first breast cancer:
pT1-2 143 (73.7%) 123 (76.9%) 0.83108
pT3-4 43 (22.2%) 35 (21.9%)
pN0 88 (45.4%) 79 (49.4%) 0.47897
pN+ 105 (54.1%) 81 (50.6%)
Treatment methods:
Radiotherapy          No 127 (65.5%) 114 (71.3%) 0.24513
                                    Yes 67 (34.5%) 46 (28.8%)
Chemotherapy       No 111 (57.2%) 106 (66.3%) 0.08244
                                    Yes 83 (42.8%) 54 (33.8%)
Tamoxifen                No 145 (74.7%) 82 (51.3%) < 0.00001
                                    Yes 49 (25.3%) 78 (48.8%)
Time interval between diagnosis of first breast cancer and metachronous primary cancer (monthsb):
Mean value  108 92.5 0.06533a
≤ 60  69 (35.6%) 65 (40.6%) 0.32881
> 60 125 (64.4%) 95 (59.4%)
ap value from Student’s t-test, other p for chi-square test, bmonths after diagnosis of first breast cancer
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in age and menopausal status. Younger age (< 50 years) and 
premenopausal status were significantly more frequently 
observed in patients with matachronous contralateral bre-
ast cancer (56.2% and 69.9%, respectively) in comparison 
to other types of metachronous malignancies (34.4% and 
48.8%, respectively). Another significant difference was ob-
served in tamoxifen intake; patients with metachronous 
contralateral breast cancer more frequently did not receive 
tamoxifen (74.7%) in comparison to 51.1% who developed 
other types of metachronous malignancies. It is important to 
note that analysed patients were managed over the period 
of 47 years (breast cancers diagnosed between 1963 and 
2010), and in this time interval the diagnostic methods and 
the spectra of treatment changed along with the indications, 
e.g. application of tamoxifen.
It is known that the elevated risk of subsequent can-
cer which developed in breast cancer survivors is related 
to hormonal (estrogen and progesteron) receptor status 
[26, 35].
Estrogen receptor-negative breast cancer is related to 
an increased risk of subsequent lung cancer. Schonfeld et 
al. presented that the lung cancer rate was significantly ele-
vated after treatment of estrogen receptor-negative breast 
cancer. These authors showed a 22% increase in the risk of 
lung cancer in estrogen receptor-negative vs estrogen re-
ceptor-positive breast cancer patients [35]. It is important to 
Figure 3. The probability of overall survival in patients with metachronous primaries developed after first breast cancer
Figure 2. The probability of overall survival according to the type of metachronous primary cancer: breast vs non-breast cancer
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mention that estrogen receptor-negative tumours are more 
frequent in younger patients with breast cancer.
In patients with expression of estrogen/progesterone re-
ceptors (ER/PR), the risk of second malignancy is associated 
with hormonal therapy (especially tamoxifen). Tamoxifen is 
used for treatment of ER/PR-positive breast cancers and for 
primary breast cancer prevention. However, this drug may 
increase the risk of other primary malignancies [26, 36–38]. 
Endometrium and gastrointestinal organs (colorectum, sto-
mach and liver) may be target sites for tamoxifen-induced car-
cinogenesis [36]. The risk of endometrial cancer increases with 
the time of tamoxifen usage; the relative risk rises from 2.0 for 
2–5 years to 6.9 for at least 5 years, p < 0.001 [37]. Additionally, 
tamoxifen users have a worse prognosis of endometrial cancer 
due to less favourable histology and a higher stage of disease. 
The above-mentioned hormonotherapy as well as cyto-
toxic and radiation therapy used in breast cancer patients 
can increase the risk of occurrence of second malignancies 
[3, 4, 6, 20, 22, 24, 26, 36, 37, 39–46].
The results of the Danish national population-based study 
published by Grantzau et al. showed that radiotherapy-treated 
early breast cancer patients have a small but significantly ele-
vated risk of second cancers [46]. The hazard ratio is 1.34 for 
radiotherapy-associated sites (lung cancer, esophageal cancer, 
soft tissue sarcoma) and for the time period of 10–14 years (HR 
= 1.55) and over 15 years after therapy (HR = 1.79). The results 
of Dutch Population-Based Study presented by Schaapveld 
et al., however, showed that in patients with breast cancer the 
10-year cumulative incidence of second non-breast cancer was 
5.4% [24]. Among patients younger than 50 years, radiotherapy 
was associated with increased lung cancer risk (HR = 2.31), 
while chemotherapy — with decreased risk of all second non-
-breast cancers (HR = 0.78). In patients aged 50 years and older, 
radiotherapy was associated with elevated risk of soft tissue 
sarcomas (HR = 3.43), while chemotherapy — with increased 
risk of melanoma, uterine cancer and acute myeloid leukemia. 
However, hormonal therapy was associated with elevated risk 
of all second non-breast cancers (HR = 1.1) and it especially 
raised the risk of uterine cancer (HR = 1.78) [24].
The most common second primary cancer in patients 
with breast cancer is contralateral breast cancer, which ac-
counts for approximately 50% of all second cancers and 
4.2% of all breast cancers [47]. Breast cancer patients have 
an increased risk (2–6 times) of occurrence of contralateral 
breast cancer, which occurs as metachronous malignancy 
at a rate of 0.13% per year and significantly more frequently 
in lower stages of disease [48].
In the presented group of metachronous malignancies, 
contralateral breast cancer comprised 54.8% (194 cases) of 
all second cancers. 
The risk of contralateral breast cancer is increased with 
positive family history, early age and stage IIB at diagnosis 
first breast cancer, estrogen/progesterone receptor-negati-
ve breast cancer, and lobular histology. Chemotherapy and 
tamoxifen reduce this risk, but the data concerning the role 
of radiotherapy as well as reproductive, environmental and 
other factors are inconsistent [27, 28, 30–32, 45, 49–52]. 
The possible impact of radiotherapy on development of 
contralateral breast cancer after treatment of first breast cancer 
remains undefined. Some authors showed the relationship 
between high dose volume and second cancer sites (lung, 
esophagus, pleura, bone, soft tissues, contralateral breast) 
but these risks decreased with increasing age and amount of 
time elapsed since treatment [20, 22, 45]. On the other hand, 
technological development in radiotherapy and the use of 
techniques with minimized scattered radiation can reduce 
this risk and, therefore, the frequency of cancers developed in 
high dose volume are strongly associated with environmental 
and lifestyle factors, and other therapeutic methods can influ-
ence this frequency [29, 50]. Lobular type of breast cancer is 
positively (over 2 times) associated with the development of 
a contralateral breast cancer [32–34, 53]. In our group, me-
tachronous contralateral breast cancer developed in 13 of 
15 (86.7%) patients with lobular first breast cancer.
The advances and effectiveness of breast cancer therapy 
resulted in the improvement of the survival rate. Elevated 
risk of occurrence of second malignancies in breast cancer 
survivors makes early detection of metachronous malignan-
cies obligatory. These patients should be placed under much 
closer post-treatment surveillance in regard to screening 
procedures (e.g. mammography, breast MRI, colonoscopy, 
abdominal and transvaginal ultrasonography). Because of 
the clinical and physiological importance of this problem, 
early detection of second and higher-order primary mali-
gnancies is an important factor which influences the quality 
of life in breast cancer survivors.
Conclusions
1.  The most frequent type of metachronous malignancy 
in patients with breast cancer is contralateral breast 
cancer (54.8% cases).
2.  Patients with contralateral breast cancer in compa-
rison to other types of metachronous malignancies 
were younger (under 50 years) and premenopausal, 
had lobular type of first breast cancer and rarely received 
tamoxifen (25.3% vs 48.2%). They had a significantly 
better prognosis than patients with other types of me-
tachronous malignancies (10-year overall survival rates 
were 80.1% vs 67.8%, p = 0.0271).
3.  The breast cancer survivors have an indication for some 
screening procedures, because the early detection of 
second and higher-order primary malignancies is an 
important factor which influences the quality of life in 
breast cancer survivors.
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